Alzheimer'
Conditions
Interventions
None listed
Sponsors
Kagawa University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Those who meet all of the following criteria are included in this study: 1) Patients who are admitted into the institutions 2) Patients with Alzheimer's disease 3) Patients who are on rivastigmine for the first time as for dementia medications, within the range of a health insurance coverage (also patients switching to rivastigmine from other medication can participate in this study) 4) Patients who are diagnosed as having decreased appetite, and needed assistance at mealtime 5) Patients who can sign and return their consent form, or their proxies can provide written consent on behalf of the patients
Exclusion criteria
Exclusion criteria: Patients who fall into any of the following criteria are excluded from this study: 1) Patients with a history of hypersensitivity to components of rivastigmine or to carbamate derivative 2) Patients with physical disabilities which interfere their food intake 3) Patients with life threating disease such as malignancy, pneumonia, etc. 4) Patients with a gastrointestinal disorder 5) Patients with conditions that are judged by physicians to be inappropriate to this study 6) Patients who need to start, or continue to use donepezil hydrochloride (drugs for dementia of Alzheimer type and Levy body), or galantamine hydrobromide (drug for dementia of Alzheimer type)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amount of meal actually eaten (average weight [%] of each meal eaten at each observation point) | — |
Secondary
| Measure | Time frame |
|---|---|
| Following outcomes are evaluated for the amount of changes: 1. Time spend on lunch 2. Body weight 3. Scores of NPI-NH 4. Scores of MMSE | — |
Countries
Japan
Contacts
Public ContactHiroki Takayama
Soiken Inc. Division of Clinical Study Support
Outcome results
None listed